Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Corticosteroids for Newly Diagnosed Chronic GVHD
NCT00350545Phase 2Completed
- Sponsor
- Stanford University
- Start
- Aug 2006
- Primary completion
- May 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Stanford University. Started Aug 2006; status: completed.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00350545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00350545.